Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Ambetter Health Insurance lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
9.25.2019

FDA Warns of Cancer-Causing Substance in Heartburn Drug Zantac

By Brian Lynch
In The News, For Consumers

With thousands of drugs available to consumers, both by prescription and over-the-counter, it should surprise no one that a large percentage pose safety risks. Many drugs present dangerous side effects or contain properties that can be hazardous to our health. But when unintended substances make their way into a drug, it can be difficult to detect and carry severe consequences. This has occurred more frequently over the past few years and has recently made headlines with the FDA warning that it has detected a cancer-causing contaminant in the heartburn drug Zantac.

The carcinogen in question, a nitrosamine impurity called N-nitrosodimethylamine (NDMA), was detected in samples of Zantac tested by the FDA. If NDMA sounds familiar, it may be because it was also found by the FDA in contaminated samples of the blood pressure medication Valsartan in July 2018.

NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

A spokesman for Sanofi, the company which sells the brand-name version of Zantac, confirmed the company has no plans to recall the product at this time.

“Sanofi takes patient safety seriously, and we are committed to working with the F.D.A.,” the spokeswoman, Ashleigh Koss, said in a statement. The over-the-counter version of Zantac “has been around for over a decade and meets all the specified safety requirements for use in the O.T.C. market.”

An FDA spokesman announced that the agency is still investigating the source and severity of the contamination, stating that it is unclear how many companies’ products are affected. However, the spokesman did confirm that of the small number of products tested for the impurity, all have contained NDMA at low levels.

While it may be too early to confirm where the NDMA contamination originated from, industry experts are suggesting the issue lies in the lax oversight of drug manufacturing in countries like China that frequently make their way to the US.

“I think this is another good example of how our regulations need to change,” said Dinesh Thakur, a drug-safety advocate in an interview with the New York Times. “Things like this will never get caught, unless somebody is actually actively looking for stuff.”

As a result of the contamination, the FDA is advising concerned patients taking over-the-counter versions of Zantac to consider switching to another medication. The agency has not, however, recommended a recall of the drug.

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • The Firm
    • Around The World
    • Chicago
  • You Should Know
    • For Businesses
    • For Consumers
    • For Investors
  • Media Appearances
  • Cases
  • Facebook
  • Twitter
  • LinkedIn
Image

55 W Monroe St. Suite 3300
Chicago, IL 60603
P_312.346.2222
F_312.346.0022

 

333 University Ave. Suite 200
Sacramento, CA 95825
P_916.565.7692
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP